Meeting
2018 ASCO Annual Meeting
Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
Authors
Karen Thudium Mueller
Novartis Institutes for BioMedical Research, East Hanover, NJ
Karen Thudium Mueller , Stephan A. Grupp , Shannon L. Maude , John E. Levine , Michael Pulsipher , Michael W. Boyer , Keith Jason August , Gary Douglas Myers , Rakesh Awasthi , Edward K Waldron , Lida Bubuteishvili-Pacaud , Tanya Taran , Mariana Cota , Constantine Si Lun Tam , Ulrich Jäger , Ronan Foley , Peter Borchmann , Stephen J. Schuster , Edmund K. Waller , Theodore Willis Laetsch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02435849, NCT02228096, NCT02445248
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3044)
DOI
10.1200/JCO.2018.36.15_suppl.3044
Abstract #
3044
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Olalekan O. Oluwole
Poster
2023 ASCO Annual Meeting
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Bijal D. Shah
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2020 ASCO Virtual Scientific Program
Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
First Author: Joerg Krueger